Pretransplantation characteristics and outcomes of patients refractory to fludarabine therapy
Age, y . | Salvage chemotherapy . | Donor . | Status at HCT . | Best response after HCT . | Outcome . |
|---|---|---|---|---|---|
| 50 | CHOP (Richter transformation) | MR | PD | CR | Relapsed shortly after HCT. Unresponsive to DLI. Died of PD. |
| 51 | Alemtuzumab, CHOP | mMU | PR | CR | Delayed graft rejection. Alive in clinical CR, but with increased proportion of CD5/CD19+ cells. |
| 56 | CHOP, alemtuzumab, | mMU | PR | PR | Delayed graft failure. Died of RSV pneumonia after top-up transplantation. |
| 47 | Alemtuzumab | MR | PR | PR | Lack of platelet engraftment. Died of PTLD after top-up transplantation. |
| 52 | Rituximab | MR | PR | PR | Ganciclovir-induced graft failure. Alive in PR (persistent thrombocytopenia). |
| 62 | Rituximab | MR | PR | CR | Relapse 5 mo after HCT. Alive with PD. |
| 57 | None | MU | PD | CR | Alive in CR. |
| 51 | CHOP, alemtuzumab, rituximab | MU | PD | PD | Never responded to any therapy. Died of PD. |
| 56 | Alemtuzumab | MU | PR | CR | Relapse 3 mo after HCT. Complete response to DLI. Alive in CR. |
| 59 | HDMP, alemtuzumab | mMU | PR | NA | Died of neutropenic sepsis on d 12. |
| 67 | Rituximab | MR | PD | CR | Died of fungal cerebral abscess 3.5 mo after HCT. |
Age, y . | Salvage chemotherapy . | Donor . | Status at HCT . | Best response after HCT . | Outcome . |
|---|---|---|---|---|---|
| 50 | CHOP (Richter transformation) | MR | PD | CR | Relapsed shortly after HCT. Unresponsive to DLI. Died of PD. |
| 51 | Alemtuzumab, CHOP | mMU | PR | CR | Delayed graft rejection. Alive in clinical CR, but with increased proportion of CD5/CD19+ cells. |
| 56 | CHOP, alemtuzumab, | mMU | PR | PR | Delayed graft failure. Died of RSV pneumonia after top-up transplantation. |
| 47 | Alemtuzumab | MR | PR | PR | Lack of platelet engraftment. Died of PTLD after top-up transplantation. |
| 52 | Rituximab | MR | PR | PR | Ganciclovir-induced graft failure. Alive in PR (persistent thrombocytopenia). |
| 62 | Rituximab | MR | PR | CR | Relapse 5 mo after HCT. Alive with PD. |
| 57 | None | MU | PD | CR | Alive in CR. |
| 51 | CHOP, alemtuzumab, rituximab | MU | PD | PD | Never responded to any therapy. Died of PD. |
| 56 | Alemtuzumab | MU | PR | CR | Relapse 3 mo after HCT. Complete response to DLI. Alive in CR. |
| 59 | HDMP, alemtuzumab | mMU | PR | NA | Died of neutropenic sepsis on d 12. |
| 67 | Rituximab | MR | PD | CR | Died of fungal cerebral abscess 3.5 mo after HCT. |
CHOP indicates cyclophosphamide-doxorubicin-vincristine-prednisone; HDMP, high-dose methyl-prednisolone; MR, matched related; PD, progressive disease; CR, complete remission; DLI, donor lymphocyte infusions; mMU, mismatched unrelated; PR, partial remission; RSV, respiratory syncytial virus; and PTLD, posttransplantation lymphoproliferative disorder; MU, matched unrelated; NA, not assessed.